Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and cures more than 60% of patients. Salvage high-dose chemotherapy with autologous stem cell transplant remains the standard second-line treatment for relapsed or refract...

Descripción completa

Detalles Bibliográficos
Autor principal: González Barca, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344863/
https://www.ncbi.nlm.nih.gov/pubmed/35928819
http://dx.doi.org/10.3389/fimmu.2022.909008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344863/
https://www.ncbi.nlm.nih.gov/pubmed/35928819
http://dx.doi.org/10.3389/fimmu.2022.909008

Ejemplares similares